Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…

Twist Bioscience Corp
Next earnings Aug 3, 2026 · consensus $-0.51 EPS, $117M rev
Last earnings -7.0% on 2026-05-04
Synthetic-DNA leader growing 20% with losses shrinking fast toward breakeven — encouraging, but 14x sales still bakes in a lot.
Twist Bioscience is the leading provider of synthetic DNA manufactured on a proprietary silicon-chip platform, selling into NGS tools, synthetic biology and biopharma. The FY2025 trajectory is the encouraging part of the story: revenue grew 20.3% to $377M, and the bottom line improved dramatically — the net loss narrowed to -$77.7M from -$209M (a 62.8% improvement), the operating loss shrank to -$136M, and operating cash burn fell to -$47.6M (a 25.7% improvement). The company is clearly executing on a path from growth-at-all-costs toward operating leverage, even trimming R&D 11.6% to $80.3M while still growing the top line.
Sources: SEC EDGAR (CIK 0001581280, latest 10-Q filed 2026-05-04) · EODHD · analysis by claude-code · as of 6/21/2026, 9:00:30 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $132M | $204M | $245M | $313M | $377M |
| Gross profit | — | — | — | — | — |
| Operating income | -$153M | -$235M | -$217M | -$221M | -$136M |
| Net income | -$152M | -$218M | -$205M | -$209M | -$77.7M |
| Diluted EPS | -$3.15 | -$4.04 | -$3.60 | -$3.60 | -$1.30 |
| Net margin | -114.9% | -107.0% | -83.5% | -66.7% | -20.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
1482 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Last 90 days: 0 open-market buys · 13 sales
| 2026-06-15 | Green Paula SVP of Human Resources | Exercise | 26.1K @ $23.33 | $610K |
| 2026-06-15 | Green Paula SVP of Human Resources | Sell | 24.1K @ $81.62 | $1.97M |
| 2026-06-15 | Green Paula SVP of Human Resources | Sell | 2.03K @ $82.17 | $167K |
| 2026-06-08 | Cho Dennis See Remarks | Sell | 402.00 @ $69.84 | $28.1K |
| 2026-06-08 | Green Paula SVP of Human Resources | Sell | 884.00 @ $69.84 | $61.7K |
| 2026-06-08 | Leproust Emily M. Chief Executive Officer | Sell | 2.27K @ $69.84 | $158K |
| 2026-06-08 | WERNER ROBERT F. Chief Accounting Officer | Sell | 232.00 @ $69.84 | $16.2K |
| 2026-06-08 | WERNER ROBERT F. Chief Accounting Officer | Sell | 1.13K @ $69.07 | $77.8K |
| 2026-06-08 | WERNER ROBERT F. Chief Accounting Officer | Gift | 500.00 | |
| 2026-05-29 | Cho Dennis See Remarks | Sell | 14.2K @ $69.75 | $991K |
| 2026-05-29 | Laponis Adam Chief Financial Officer | Sell | 4.00K @ $70.00 | $280K |
| 2026-05-28 | Leproust Emily M. Chief Executive Officer | Exercise | 16.5K @ $8.82 | $145K |
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.